BiomeCRC® introduced at one of the most prestigious Gastroenterology conferences in the world
VIENNA, October 11th: BiomeDx was present at the UEG Week (https://ueg.eu/week) conference in Vienna. Early results on the development of BiomeCRC® have been received with a lot of interest and excitement. Katarina Priselac from BiomeDx has presented these results in a poster presentation, which summarises a huge part of the work conducted during her Master thesis.
BiomeCRC is a colorectal cancer preventive screening test based on the intestinal microbiome. The tool is powered by the proven BiomeDx platform and data from numerous clinical trials. Ongoing research in collaboration with the Medical University of Vienna includes over 1000 probands. Read more on BiomeCRC.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
Presented poster: Analysis of colorectal cancer and adenoma microbiome signatures and the application of machine learning classification as a potential screening tool
Follow us on LinkedIn